Medicus Pharma (NASDAQ:MDCX) announced that its SKNJCT-003 Phase 2 study, evaluating the efficacy of two dose levels of D-MNA for the treatment of nodular basal cell carcinoma (BCC), has now randomized more than 50% of the 60 patients targeted for enrollment.
The company also reports that it remains on track to complete an interim data analysis by the end of Q1 2025 and submit its findings to the FDA as part of a Type C meeting request in Q2 2025.
According to Medicus, the Type C meeting aims to formally discuss product development and further align on the clinical pathway. The company seeks the FDA’s consent to expedite the clinical development program.
